METHODS: Adult hospitalized patients administered at least 5 days of cefiderocol as definitive treatment from October 1, 2020 to September 16, 2021 were included in this retrospective cohort analysis. The primary outcome was clinical success defined as a composite of 30 day survival, resolution of infection, and absence of 30 day recurrence of the same organism.
RESULTS: Among 24 patients, pneumonia (19, 79%) was the most common source of infection with Acinetobacter baumannii (14, 58%) and P. aeruginosa (10, 42%) as the predominant organisms isolated. Cefiderocol monotherapy was used as definitive treatment in 16 (67%) patients. Eleven patients (46%) met clinical success. Thirty-day mortality occurred in ten (42%) patients while seven (29%) patients had recurrence of infection. Thirteen out of 21 total isolates (62%) tested for susceptibility were deemed susceptible. Of the 16 patients with available susceptibility, 9 (56%) had an infection where all isolated organisms were susceptible to cefiderocol.
CONCLUSIONS: Our results provide additional insight into the in vivo activity of cefiderocol. Cefiderocol remains a salvage option for carbapenem-resistant Gram-negative organisms.
方法:本回顾性队列分析包括2020年10月1日至2021年9月16日给予头孢地洛至少5天作为确定性治疗的成年住院患者。主要结果是临床成功定义为30天生存的复合,感染的解决,并且没有相同生物体的30天复发。
结果:在24名患者中,肺炎(19,79%)是最常见的感染源,鲍曼不动杆菌(14,58%)和铜绿假单胞菌(10,42%)是分离的主要生物。头孢地洛单药治疗16例(67%)患者被用作确定性治疗。11名患者(46%)达到临床成功。10例(42%)患者死亡30天,而7例(29%)患者感染复发。在经过敏感性测试的21个分离株中,有13个(62%)被认为是易感的。在16名具有易感性的患者中,9(56%)感染了所有分离的生物都对头孢地洛敏感。
结论:我们的结果为头孢地洛的体内活性提供了更多的见解。头孢地洛仍然是耐碳青霉烯类革兰氏阴性菌的挽救选择。